Most TCR Sequencing Data Holds More Signal Than the Analysis Ever Surfaces: Webinar on a Free ImmuneWatch x QIAGEN Grant

Most TCR sequencing data holds more clinical signal than the analysis ever pulls out of it. Longitudinal clone tracking, expansion or contraction patterns, and antigen-specific T-cell activity are all there, whether the underlying question is mechanism-of-action, immune monitoring, or a milestone for the next funding round.

ImmuneWatch and QIAGEN are funding that analysis directly for up to 4 research projects, 2 academic, 2 biopharma, at no cost to the recipients:

• QIAGEN's RNA extraction kit, shipped directly to the lab
• QIAseq Targeted RNA TCR Panel library preparation
• Full NGS sequencing and clonotype data processing
• TCR clustering and antigen-TCR annotation from ImmuneWatch DETECT analysts

Awards cover up to 24 samples and complete within 6 months, with priority for projects in cancer and autoimmunity: longitudinal TCR clone tracking, clonal expansion or contraction, and immune monitoring across immunotherapy, cell therapy, or vaccine trials. Applications close 30 October 2026.

Join the live webinar on 2 September 2026 at 16:00 CEST, where ImmuneWatch will walk through the grant application process and share real examples of how the team approaches TCR sequencing projects and analysis more broadly, grant or no grant.